Basilea to acquire fosmanogepix, a clinical-stage broad-spectrum antifungal candidate, from Amplyx Pharmaceuticals
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action.
Lenz & Staehelin is advising Pfizer Inc. and Amplyx Pharmaceuticals on this transaction. The team includes Tino Gaberthüel (partner, M&A), Vincent Huynh Dac (associate, M&A) and Stephan Brander (counsel, Tax).